Person · CIK 1528185

Helen Torley

PRESIDENT AND CEO at Halozyme Therapeutics

Earlier: Quest Diagnostics, Relypsa and Onyx Pharmaceuticals

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$107.6M

Noticed on Form 144$44.1M

Bought on Form 4$446K

Companies4

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

Company	Security	Held	Shares or units	As of
Halozyme Therapeutics HALO	Common Stock	Directly	767,780	Oct 8, 2026 · Filing · EDGAR
Halozyme Therapeutics HALO	Option to Purchase Common Stock exercise $18.41, expires Feb 14, 2028, into Common Stock	Directly	21,552	Oct 8, 2026 · Filing · EDGAR
Quest Diagnostics	Common Stock	Directly	6,260	May 25, 2021 · Filing · EDGAR
Quest Diagnostics	Non-Qualifed Stock Option (right to buy) exercise $108.35, expires Oct 1, 2028, into Common Stock	Directly	1,298	Oct 1, 2018 · Filing · EDGAR

Sold and noticed by quarter

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table

Quarter	Sold (Form 4)	Noticed (Form 144)	Bought (Form 4)
Q4 2026	$6.6M	—	—
Q3 2026	$12.9M	Not machine-readable	—
Q2 2026	$10M	Not machine-readable	—
Q1 2026	$7.3M	$11.2M	—
Q4 2025	$9.6M	$10M	—
Q3 2025	$11.6M	—	—
Q2 2025	$3.2M	$12.8M	—
Q4 2024	$1.1M	$1.1M	—
Q3 2024	$5.2M	$5.2M	—
Q3 2023	$3.9M	$3.9M	—
Q1 2023	$4.9M	Not machine-readable	—
Q4 2022	$3.3M	Not machine-readable	—
Q4 2021	$4M	Not machine-readable	—
Q3 2021	$6.5M	Not machine-readable	—
Q2 2021	$6.3M	Not machine-readable	—
Q1 2021	$4.7M	Not machine-readable	—
Q4 2020	$2M	Not machine-readable	—
Q2 2016	$20K	Not machine-readable	—
Q3 2014	—	—	$446K
Q3 2013	$1.2M	Not machine-readable	—
Q2 2013	$850K	Not machine-readable	—
Q1 2013	$649K	Not machine-readable	—
Q4 2012	$1.1M	Not machine-readable	—
Q3 2012	$617K	Not machine-readable	—

Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice date	Noticed	Planned sale	Outcome	Links
Halozyme Therapeutics HALO · J.P. Morgan Securities · 10b5-1 plan adopted Mar 21, 2025 · 3 notices
Feb 3, 2026	150,000 · ~$11.2M	Feb 3, 2026	Sold as noticed Sold 150,000 in 20 sales, Feb 3 to Apr 6 · $10.6M Form 4 (1) · Form 4 (2) · Form 4 (3) · Form 4 (4)	Filing · EDGAR
Oct 1, 2025	136,569 · ~$10M	Oct 1, 2025	Sold as noticed Sold 136,569 in 23 sales, Oct 1 to Dec 1 · $9.6M Form 4 (1) · Form 4 (2) · Form 4 (3)	Filing · EDGAR
Jun 20, 2025	240,000 · ~$12.8M	Jun 20, 2025	Sold as noticed Sold 240,000 in 24 sales, Jun 20 to Sep 4 · $14.8M Form 4 (1) · Form 4 (2) · Form 4 (3) · Form 4 (4)	Filing · EDGAR
Halozyme Therapeutics HALO · Morgan Stanley Smith Barney · 10b5-1 plan adopted Mar 22, 2024 · 11 notices
Oct 9, 2024	10,000 · ~$526K	Oct 9, 2024	Sold as noticed Sold 10,000 in 3 sales, Oct 9 to Oct 9 · $526K Form 4	Filing · EDGAR
Oct 8, 2024	10,000 · ~$540K	Oct 8, 2024	Sold as noticed Sold 10,000 in 2 sales, Oct 8 to Oct 8 · $540K Form 4	Filing · EDGAR
Sep 26, 2024	10,000 · ~$561K	Sep 26, 2024	Sold as noticed Sold 10,000 at $56.10 on Sep 26 · $561K Form 4	Filing · EDGAR
Sep 25, 2024	10,000 · ~$563K	Sep 25, 2024	Sold as noticed Sold 10,000 at $56.34 on Sep 25 · $563K Form 4	Filing · EDGAR
Sep 24, 2024	10,000 · ~$582K	Sep 24, 2024	Sold as noticed Sold 10,000 at $58.21 on Sep 24 · $582K Form 4	Filing · EDGAR
Sep 12, 2024	10,000 · ~$592K	Sep 12, 2024	Sold as noticed Sold 10,000 at $59.20 on Sep 12 · $592K Form 4	Filing · EDGAR
Sep 11, 2024	10,000 · ~$591K	Sep 11, 2024	Sold as noticed Sold 10,000 at $59.09 on Sep 11 · $591K Form 4	Filing · EDGAR
Sep 10, 2024	10,000 · ~$591K	Sep 10, 2024	Sold as noticed Sold 10,000 at $59.09 on Sep 10 · $591K Form 4	Filing · EDGAR
Aug 15, 2024	10,000 · ~$579K	Aug 15, 2024	Sold as noticed Sold 10,000 at $57.95 on Aug 15 · $579K Form 4	Filing · EDGAR
Aug 14, 2024	10,000 · ~$572K	Aug 14, 2024	Sold as noticed Sold 10,000 in 3 sales, Aug 14 to Aug 14 · $572K Form 4	Filing · EDGAR
Aug 13, 2024	10,000 · ~$562K	Aug 13, 2024	Sold as noticed Sold 10,000 at $56.25 on Aug 13 · $562K Form 4	Filing · EDGAR
Halozyme Therapeutics HALO · E*Trade Financial · 10b5-1 plan adopted Sep 7, 2022 · 9 notices
Aug 31, 2023	10,000 · ~$428K	Aug 31, 2023	Sold as noticed Sold 10,000 at $42.82 on Aug 31 · $428K Form 4	Filing · EDGAR
Aug 30, 2023	10,000 · ~$429K	Aug 30, 2023	Sold as noticed Sold 10,000 at $42.85 on Aug 30 · $429K Form 4	Filing · EDGAR
Aug 29, 2023	10,000 · ~$424K	Aug 29, 2023	Sold as noticed Sold 10,000 at $42.40 on Aug 29 · $424K Form 4	Filing · EDGAR
Aug 17, 2023	10,000 · ~$432K	Aug 17, 2023	Sold as noticed Sold 10,000 at $43.18 on Aug 17 · $432K Form 4	Filing · EDGAR
Aug 16, 2023	10,000 · ~$435K	Aug 16, 2023	Sold as noticed Sold 10,000 at $43.53 on Aug 16 · $435K Form 4	Filing · EDGAR
Aug 15, 2023	10,000 · ~$438K	Aug 15, 2023	Sold as noticed Sold 10,000 at $43.77 on Aug 15 · $438K Form 4	Filing · EDGAR
Jul 27, 2023	10,000 · ~$438K	Jul 27, 2023	Sold as noticed Sold 10,000 at $43.79 on Jul 27 · $438K Form 4	Filing · EDGAR
Jul 26, 2023	10,000 · ~$427K	Jul 26, 2023	Sold as noticed Sold 10,000 at $42.69 on Jul 26 · $427K Form 4	Filing · EDGAR
Jul 25, 2023	10,000 · ~$428K	Jul 25, 2023	Sold as noticed Sold 10,000 at $42.80 on Jul 25 · $428K Form 4	Filing · EDGAR
Sales without a matching Form 144 · 112 sales No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt.
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 200 at $110.51 on Oct 8, 2026 · $22K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 11,900 at $110.00 on Oct 8, 2026 · $1.3M (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 3,090 at $108.91 on Oct 8, 2026 · $337K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 4,810 at $108.18 on Oct 8, 2026 · $520K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 200 at $113.69 on Oct 7, 2026 · $23K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 900 at $112.78 on Oct 7, 2026 · $102K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 10,300 at $111.84 on Oct 7, 2026 · $1.2M (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 8,600 at $111.03 on Oct 7, 2026 · $955K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 1,780 at $110.81 on Oct 6, 2026 · $197K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 9,920 at $109.89 on Oct 6, 2026 · $1.1M (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 6,000 at $109.33 on Oct 6, 2026 · $656K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 2,300 at $107.90 on Oct 6, 2026 · $248K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 4,508 at $107.55 on Sep 11, 2026 · $485K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 15,492 at $107.15 on Sep 11, 2026 · $1.7M (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 5,412 at $107.58 on Sep 10, 2026 · $582K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 14,588 at $107.01 on Sep 10, 2026 · $1.6M (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 100 at $108.67 on Sep 9, 2026 · $11K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 6,596 at $107.82 on Sep 9, 2026 · $711K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 13,304 at $107.22 on Sep 9, 2026 · $1.4M (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 3,200 at $107.77 on Aug 19, 2026 · $345K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 9,600 at $107.22 on Aug 19, 2026 · $1M (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 7,200 at $106.36 on Aug 19, 2026 · $766K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 9,400 at $104.87 on Aug 18, 2026 · $986K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 4,897 at $104.11 on Aug 18, 2026 · $510K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 5,703 at $103.08 on Aug 18, 2026 · $588K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 7,500 at $103.48 on Aug 17, 2026 · $776K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 9,000 at $102.55 on Aug 17, 2026 · $923K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 2,100 at $101.77 on Aug 17, 2026 · $214K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 500 at $100.46 on Aug 17, 2026 · $50K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 900 at $98.96 on Aug 17, 2026 · $89K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 1,035 at $80.19 on Jul 8, 2026 · $83K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 888 at $79.28 on Jul 8, 2026 · $70K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 6,100 at $69.69 on Jun 3, 2026 · $425K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 2,000 at $68.74 on Jun 3, 2026 · $137K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 1,500 at $67.68 on Jun 3, 2026 · $102K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 400 at $66.37 on Jun 3, 2026 · $27K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 3,400 at $66.75 on Jun 2, 2026 · $227K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 16,600 at $66.31 on Jun 2, 2026 · $1.1M (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 5,401 at $68.35 on Jun 1, 2026 · $369K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 12,989 at $67.41 on Jun 1, 2026 · $876K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 1,610 at $66.39 on Jun 1, 2026 · $107K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 600 at $70.81 on May 13, 2026 · $42K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 3,950 at $69.79 on May 13, 2026 · $276K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 3,350 at $68.88 on May 13, 2026 · $231K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 2,100 at $68.10 on May 13, 2026 · $143K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 2,800 at $73.12 on May 12, 2026 · $205K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 5,900 at $72.15 on May 12, 2026 · $426K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 9,802 at $71.37 on May 12, 2026 · $700K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 1,398 at $70.29 on May 12, 2026 · $98K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 100 at $67.85 on May 12, 2026 · $7K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 6,700 at $66.33 on May 11, 2026 · $444K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 3,575 at $65.46 on May 11, 2026 · $234K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Halozyme Therapeutics (HALO): Sold 9,725 at $64.63 on May 11, 2026 · $629K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 10,000 at $42.73 on Mar 9, 2023 · $427K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 10,000 at $43.26 on Mar 8, 2023 · $433K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 10,000 at $45.47 on Mar 7, 2023 · $455K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 11,061 at $49.26 on Feb 16, 2023 · $545K	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 10,000 at $50.40 on Feb 9, 2023 · $504K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 10,000 at $51.36 on Feb 8, 2023 · $514K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 10,000 at $51.26 on Feb 7, 2023 · $513K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 10,000 at $52.41 on Jan 19, 2023 · $524K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 10,000 at $51.05 on Jan 18, 2023 · $510K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 1,103 at $50.93 on Jan 17, 2023 · $56K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 8,897 at $50.40 on Jan 17, 2023 · $448K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 896 at $58.20 on Dec 15, 2022 · $52K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 9,104 at $57.29 on Dec 15, 2022 · $522K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 10,000 at $58.30 on Dec 14, 2022 · $583K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 493 at $59.12 on Dec 13, 2022 · $29K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 9,507 at $58.64 on Dec 13, 2022 · $557K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 10,000 at $52.15 on Nov 17, 2022 · $521K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 10,000 at $53.90 on Nov 16, 2022 · $539K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 13 at $54.61 on Nov 15, 2022 · $710 (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 9,987 at $54.11 on Nov 15, 2022 · $540K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 12,225 at $40.42 on Nov 8, 2021 · $494K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 37,775 at $39.62 on Nov 8, 2021 · $1.5M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 5,857 at $40.95 on Oct 4, 2021 · $240K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 44,143 at $39.97 on Oct 4, 2021 · $1.8M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 6,560 at $42.98 on Sep 7, 2021 · $282K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 43,440 at $42.29 on Sep 7, 2021 · $1.8M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 1,048 at $46.11 on Aug 10, 2021 · $48K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 500 at $44.91 on Aug 10, 2021 · $22K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 400 at $43.26 on Aug 10, 2021 · $17K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 1,000 at $42.64 on Aug 10, 2021 · $43K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 21,914 at $41.47 on Aug 10, 2021 · $909K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 25,138 at $40.42 on Aug 10, 2021 · $1M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 50,000 at $45.97 on Jul 6, 2021 · $2.3M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 50,000 at $39.66 on Jun 7, 2021 · $2M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 1,066 at $44.84 on May 11, 2021 · $48K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 3,956 at $44.11 on May 11, 2021 · $174K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 36,522 at $43.05 on May 11, 2021 · $1.6M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 8,456 at $42.17 on May 11, 2021 · $357K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 50,000 at $42.55 on Apr 5, 2021 · $2.1M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 33,890 at $46.48 on Mar 1, 2021 · $1.6M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 16,110 at $45.58 on Mar 1, 2021 · $734K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 5,437 at $48.51 on Feb 1, 2021 · $264K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 44,563 at $47.76 on Feb 1, 2021 · $2.1M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 27,674 at $41.18 on Nov 25, 2020 · $1.1M	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 22,326 at $40.17 on Nov 25, 2020 · $897K	Filing · EDGAR
—	—	—	Notice not machine-readable Relypsa: Sold 1,013 at $19.32 on Jun 7, 2016 · $20K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 1,061 at $126.93 on Aug 12, 2013 · $135K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 8,250 at $126.89 on Aug 12, 2013 · $1M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 1,000 at $97.26 on May 13, 2013 · $97K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 2,500 at $98.28 on May 13, 2013 · $246K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 3,000 at $98.78 on May 13, 2013 · $296K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 1,750 at $97.32 on May 13, 2013 · $170K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 466 at $86.14 on Apr 1, 2013 · $40K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 8,250 at $78.61 on Feb 4, 2013 · $649K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 11,997 at $75.22 on Nov 12, 2012 · $902K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 2,314 at $86.51 on Oct 4, 2012 · $200K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 1,878 at $72.78 on Sep 4, 2012 · $137K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 2,000 at $71.89 on Aug 6, 2012 · $144K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 4,549 at $73.97 on Jul 25, 2012 · $336K (10b5-1 plan)	Filing · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

Halozyme Therapeutics HALO President and CEO · filings 2014 to 2026 · sold $103.2M · bought $446K · $44.1M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Oct 8, 2026	Option or RSU exercised or converted	+20,000	$18.41	$368K	787,780 direct	Filing · EDGAR
Oct 8, 2026	Sale under a 10b5-1 plan	−4,810	$108.18	$520K	782,970 direct	Filing · EDGAR
Oct 8, 2026	Sale under a 10b5-1 plan	−3,090	$108.91	$337K	779,880 direct	Filing · EDGAR
Oct 8, 2026	Sale under a 10b5-1 plan	−11,900	$110.00	$1.3M	767,980 direct	Filing · EDGAR
Oct 8, 2026	Sale under a 10b5-1 plan	−200	$110.51	$22K	767,780 direct	Filing · EDGAR
Oct 8, 2026	Option or RSU exercised or converted Option to Purchase Common Stock	−20,000	$18.41	$368K	21,552 direct	Filing · EDGAR
Oct 7, 2026	Option or RSU exercised or converted	+20,000	$18.41	$368K	787,780 direct	Filing · EDGAR
Oct 7, 2026	Sale under a 10b5-1 plan	−8,600	$111.03	$955K	779,180 direct	Filing · EDGAR
Oct 7, 2026	Sale under a 10b5-1 plan	−10,300	$111.84	$1.2M	768,880 direct	Filing · EDGAR
Oct 7, 2026	Sale under a 10b5-1 plan	−900	$112.78	$102K	767,980 direct	Filing · EDGAR
Oct 7, 2026	Sale under a 10b5-1 plan	−200	$113.69	$23K	767,780 direct	Filing · EDGAR
Oct 7, 2026	Option or RSU exercised or converted Option to Purchase Common Stock	−20,000	$18.41	$368K	41,552 direct	Filing · EDGAR
Oct 6, 2026	Option or RSU exercised or converted	+20,000	$18.41	$368K	787,780 direct	Filing · EDGAR
Oct 6, 2026	Sale under a 10b5-1 plan	−2,300	$107.90	$248K	785,480 direct	Filing · EDGAR
Oct 6, 2026	Sale under a 10b5-1 plan	−6,000	$109.33	$656K	779,480 direct	Filing · EDGAR
Oct 6, 2026	Sale under a 10b5-1 plan	−9,920	$109.89	$1.1M	769,560 direct	Filing · EDGAR
Oct 6, 2026	Sale under a 10b5-1 plan	−1,780	$110.81	$197K	767,780 direct	Filing · EDGAR
Oct 6, 2026	Option or RSU exercised or converted Option to Purchase Common Stock	−20,000	$18.41	$368K	61,552 direct	Filing · EDGAR
Sep 11, 2026	Option or RSU exercised or converted	+20,000	$18.41	$368K	787,780 direct	Filing · EDGAR
Sep 11, 2026	Sale under a 10b5-1 plan	−15,492	$107.15	$1.7M	772,288 direct	Filing · EDGAR
Sep 11, 2026	Sale under a 10b5-1 plan	−4,508	$107.55	$485K	767,780 direct	Filing · EDGAR
Sep 11, 2026	Option or RSU exercised or converted Option to Purchase Common Stock	−20,000	$18.41	$368K	81,552 direct	Filing · EDGAR
Sep 10, 2026	Option or RSU exercised or converted	+20,000	$18.41	$368K	787,780 direct	Filing · EDGAR
Sep 10, 2026	Sale under a 10b5-1 plan	−14,588	$107.01	$1.6M	773,192 direct	Filing · EDGAR
Sep 10, 2026	Sale under a 10b5-1 plan	−5,412	$107.58	$582K	767,780 direct	Filing · EDGAR
Sep 10, 2026	Option or RSU exercised or converted Option to Purchase Common Stock	−20,000	$18.41	$368K	101,552 direct	Filing · EDGAR
Sep 9, 2026	Option or RSU exercised or converted	+20,000	$18.41	$368K	787,780 direct	Filing · EDGAR
Sep 9, 2026	Sale under a 10b5-1 plan	−13,304	$107.22	$1.4M	774,476 direct	Filing · EDGAR
Sep 9, 2026	Sale under a 10b5-1 plan	−6,596	$107.82	$711K	767,880 direct	Filing · EDGAR
Sep 9, 2026	Sale under a 10b5-1 plan	−100	$108.67	$11K	767,780 direct	Filing · EDGAR
Sep 9, 2026	Option or RSU exercised or converted Option to Purchase Common Stock	−20,000	$18.41	$368K	121,552 direct	Filing · EDGAR
Aug 19, 2026	Option or RSU exercised or converted	+20,000	$18.41	$368K	787,780 direct	Filing · EDGAR
Aug 19, 2026	Sale under a 10b5-1 plan	−7,200	$106.36	$766K	780,580 direct	Filing · EDGAR
Aug 19, 2026	Sale under a 10b5-1 plan	−9,600	$107.22	$1M	770,980 direct	Filing · EDGAR
Aug 19, 2026	Sale under a 10b5-1 plan	−3,200	$107.77	$345K	767,780 direct	Filing · EDGAR
Aug 19, 2026	Option or RSU exercised or converted Option to Purchase Common Stock	−20,000	$18.41	$368K	141,552 direct	Filing · EDGAR
Aug 18, 2026	Option or RSU exercised or converted	+20,000	$18.41	$368K	787,780 direct	Filing · EDGAR
Aug 18, 2026	Sale under a 10b5-1 plan	−5,703	$103.08	$588K	782,077 direct	Filing · EDGAR
Aug 18, 2026	Sale under a 10b5-1 plan	−4,897	$104.11	$510K	777,180 direct	Filing · EDGAR
Aug 18, 2026	Sale under a 10b5-1 plan	−9,400	$104.87	$986K	767,780 direct	Filing · EDGAR
Aug 18, 2026	Option or RSU exercised or converted Option to Purchase Common Stock	−20,000	$18.41	$368K	161,552 direct	Filing · EDGAR
Aug 17, 2026	Option or RSU exercised or converted	+20,000	$18.41	$368K	787,780 direct	Filing · EDGAR
Aug 17, 2026	Sale under a 10b5-1 plan	−900	$98.96	$89K	786,880 direct	Filing · EDGAR
Aug 17, 2026	Sale under a 10b5-1 plan	−500	$100.46	$50K	786,380 direct	Filing · EDGAR
Aug 17, 2026	Sale under a 10b5-1 plan	−2,100	$101.77	$214K	784,280 direct	Filing · EDGAR
Aug 17, 2026	Sale under a 10b5-1 plan	−9,000	$102.55	$923K	775,280 direct	Filing · EDGAR
Aug 17, 2026	Sale under a 10b5-1 plan	−7,500	$103.48	$776K	767,780 direct	Filing · EDGAR
Aug 17, 2026	Option or RSU exercised or converted Option to Purchase Common Stock	−20,000	$18.41	$368K	181,552 direct	Filing · EDGAR
Jul 8, 2026	Option or RSU exercised or converted	+1,923	$12.07	$23K	769,703 direct	Filing · EDGAR
Jul 8, 2026	Sale under a 10b5-1 plan	−888	$79.28	$70K	768,815 direct	Filing · EDGAR
Jul 8, 2026	Sale under a 10b5-1 plan	−1,035	$80.19	$83K	767,780 direct	Filing · EDGAR
Jul 8, 2026	Option or RSU exercised or converted Option to Purchase Common Stock	−1,923	$12.07	$23K	0 direct	Filing · EDGAR
Jun 3, 2026	Option or RSU exercised or converted	+10,000	$12.07	$121K	777,780 direct	Filing · EDGAR
Jun 3, 2026	Sale under a 10b5-1 plan	−400	$66.37	$27K	777,380 direct	Filing · EDGAR
Jun 3, 2026	Sale under a 10b5-1 plan	−1,500	$67.68	$102K	775,880 direct	Filing · EDGAR
Jun 3, 2026	Sale under a 10b5-1 plan	−2,000	$68.74	$137K	773,880 direct	Filing · EDGAR
Jun 3, 2026	Sale under a 10b5-1 plan	−6,100	$69.69	$425K	767,780 direct	Filing · EDGAR
Jun 3, 2026	Option or RSU exercised or converted Option to Purchase Common Stock	−10,000	$12.07	$121K	1,923 direct	Filing · EDGAR
Jun 2, 2026	Option or RSU exercised or converted	+20,000	$12.07	$241K	787,780 direct	Filing · EDGAR
Jun 2, 2026	Sale under a 10b5-1 plan	−16,600	$66.31	$1.1M	771,180 direct	Filing · EDGAR

487 earlier transactions are in the filing list below.

Quest Diagnostics Director · filings 2018 to 2021

Date	Transaction	Shares	Held after	Source
May 25, 2021	Grant or award from the company	+1,363	6,260 direct	Filing · EDGAR
May 19, 2020	Grant or award from the company	+1,531	4,897 direct	Filing · EDGAR
May 14, 2019	Grant or award from the company	+1,722	3,366 direct	Filing · EDGAR
Oct 1, 2018	Grant or award from the company Non-Qualifed Stock Option (right to buy)	+1,298	1,298 direct	Filing · EDGAR
Jul 2, 2018	Grant or award from the company Non-Qualifed Stock Option (right to buy)	+1,297	1,297 direct	Filing · EDGAR
Jun 1, 2018	Grant or award from the company Non-Qualifed Stock Option (right to buy)	+665	665 direct	Filing · EDGAR
May 15, 2018	Grant or award from the company	+1,644	1,644 direct	Filing · EDGAR

Relypsa Director · filings 2015 to 2016 · sold $20K

Date	Transaction	Shares	Price	Value	Held after	Source
Sep 1, 2016	Tendered in a change of control	−1,237	$32.00	$40K	2,250 direct	Filing · EDGAR
Sep 1, 2016	Returned to the company	−2,250	$32.00	$72K	0 direct	Filing · EDGAR
Sep 1, 2016	Returned to the company Stock Option (Right to Buy)	−12,000			0 direct	Filing · EDGAR
Sep 1, 2016	Returned to the company Stock Option (Right to Buy)	−4,500			0 direct	Filing · EDGAR
Sep 1, 2016	Returned to the company Stock Option (Right to Buy)	−4,500			0 direct	Filing · EDGAR
Jun 21, 2016	Grant or award from the company	+2,250			3,487 direct	Filing · EDGAR
Jun 21, 2016	Grant or award from the company Stock Option (Right to Buy)	+4,500			4,500 direct	Filing · EDGAR
Jun 7, 2016	Open-market or private sale	−1,013	$19.32	$20K	1,237 direct	Filing · EDGAR
Jun 4, 2015	Grant or award from the company	+2,250			2,250 direct	Filing · EDGAR
Jun 4, 2015	Grant or award from the company Stock Option (right to buy)	+4,500			4,500 direct	Filing · EDGAR
Jan 22, 2015	Grant or award from the company Stock Option (right to buy)	+12,000			12,000 direct	Filing · EDGAR

Onyx Pharmaceuticals EVP, Chief Commercial Officer · filings 2011 to 2013 · sold $4.4M

Date	Transaction	Shares	Price	Value	Held after	Source
Oct 1, 2013	Tendered in a change of control	−7,336	$125.00	$917K	28,575 direct	Filing · EDGAR
Oct 1, 2013	Returned to the company	−28,575	$125.00	$3.6M	0 direct	Filing · EDGAR
Oct 1, 2013	Returned to the company Stock Options	−11,868			0 direct	Filing · EDGAR
Oct 1, 2013	Returned to the company Stock Options	−44,132			0 direct	Filing · EDGAR
Oct 1, 2013	Returned to the company Stock Options	−1,144			0 direct	Filing · EDGAR
Oct 1, 2013	Returned to the company Stock Options	−12,156			0 direct	Filing · EDGAR
Oct 1, 2013	Returned to the company Stock Options	−24,300			0 direct	Filing · EDGAR
Sep 3, 2013	Shares withheld for tax or exercise price	−2,099	$123.62	$259K	35,911 direct	Filing · EDGAR
Aug 12, 2013	Option or RSU exercised or converted	+7,000	$33.70	$236K	54,646 direct	Filing · EDGAR
Aug 12, 2013	Option or RSU exercised or converted	+1,250	$37.68	$47K	55,896 direct	Filing · EDGAR
Aug 12, 2013	Sale under a 10b5-1 plan	−8,250	$126.89	$1M	47,646 direct	Filing · EDGAR
Aug 12, 2013	Sale under a 10b5-1 plan	−1,061	$126.93	$135K	46,585 direct	Filing · EDGAR
Aug 12, 2013	Option or RSU exercised or converted Stock Option (Right to Buy)	−7,000			56,000 direct	Filing · EDGAR
Aug 12, 2013	Option or RSU exercised or converted Stock Option (Right to Buy)	−1,250			13,300 direct	Filing · EDGAR
May 13, 2013	Option or RSU exercised or converted	+1,250	$37.68	$47K	48,896 direct	Filing · EDGAR
May 13, 2013	Option or RSU exercised or converted	+7,000	$33.70	$236K	55,896 direct	Filing · EDGAR
May 13, 2013	Sale under a 10b5-1 plan	−1,750	$97.32	$170K	54,146 direct	Filing · EDGAR
May 13, 2013	Sale under a 10b5-1 plan	−3,000	$98.78	$296K	51,146 direct	Filing · EDGAR
May 13, 2013	Sale under a 10b5-1 plan	−2,500	$98.28	$246K	48,646 direct	Filing · EDGAR
May 13, 2013	Sale under a 10b5-1 plan	−1,000	$97.26	$97K	47,646 direct	Filing · EDGAR
May 13, 2013	Option or RSU exercised or converted Stock Option (Right to Buy)	−7,000			63,000 direct	Filing · EDGAR
May 13, 2013	Option or RSU exercised or converted Stock Option (Right to Buy)	−1,250			14,450 direct	Filing · EDGAR
Apr 1, 2013	Sale under a 10b5-1 plan	−466	$86.14	$40K	47,646 direct	Filing · EDGAR
Mar 28, 2013	Grant or award from the company	+8,600			48,112 direct	Filing · EDGAR
Mar 28, 2013	Grant or award from the company Stock Option (Right to Buy)	+24,300			24,300 direct	Filing · EDGAR
Feb 4, 2013	Option or RSU exercised or converted	+7,000	$33.70	$236K	46,512 direct	Filing · EDGAR
Feb 4, 2013	Option or RSU exercised or converted	+1,250	$37.68	$47K	47,762 direct	Filing · EDGAR
Feb 4, 2013	Sale under a 10b5-1 plan	−8,250	$78.61	$649K	39,512 direct	Filing · EDGAR
Feb 4, 2013	Option or RSU exercised or converted Stock Option (Right to Buy)	−7,000			70,000 direct	Filing · EDGAR
Feb 4, 2013	Option or RSU exercised or converted Stock Option (Right to Buy)	−1,250			15,800 direct	Filing · EDGAR
Nov 12, 2012	Option or RSU exercised or converted	+7,000	$33.70	$236K	50,259 direct	Filing · EDGAR
Nov 12, 2012	Option or RSU exercised or converted	+1,250	$37.68	$47K	51,509 direct	Filing · EDGAR
Nov 12, 2012	Sale under a 10b5-1 plan	−11,997	$75.22	$902K	39,512 direct	Filing · EDGAR
Nov 12, 2012	Option or RSU exercised or converted Stock Option (Right to Buy)	−7,000			77,000 direct	Filing · EDGAR
Nov 12, 2012	Option or RSU exercised or converted Stock Option (Right to Buy)	−1,250			17,050 direct	Filing · EDGAR
Oct 4, 2012	Sale under a 10b5-1 plan	−2,314	$86.51	$200K	43,259 direct	Filing · EDGAR
Sep 4, 2012	Sale under a 10b5-1 plan	−1,878	$72.78	$137K	56,823 direct	Filing · EDGAR
Aug 6, 2012	Open-market or private sale	−2,000	$71.89	$144K	58,701 direct	Filing · EDGAR
Jul 25, 2012	Sale under a 10b5-1 plan	−4,549	$73.97	$336K	60,701 direct	Filing · EDGAR
Mar 30, 2012	Grant or award from the company	+3,600			48,100 direct	Filing · EDGAR
Mar 30, 2012	Grant or award from the company	+17,150			65,250 direct	Filing · EDGAR
Mar 30, 2012	Grant or award from the company Stock Option (Right to Buy)	+18,300			18,300 direct	Filing · EDGAR
Oct 26, 2011	Grant or award from the company	+10,000			44,500 direct	Filing · EDGAR
Aug 29, 2011	Grant or award from the company	+12,000			12,000 direct	Filing · EDGAR
Aug 29, 2011	Grant or award from the company	+22,500			34,500 direct	Filing · EDGAR
Aug 29, 2011	Grant or award from the company Stock Option (Right to Buy)	+84,000			84,000 direct	Filing · EDGAR

All 150 Forms 3, 4, 5 and 144

Filed	Form	Company	Links
Oct 8, 2026	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Sep 11, 2026	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Aug 19, 2026	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Aug 17, 2026	Form 144	Could not read	EDGAR
Jul 9, 2026	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Jun 3, 2026	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
May 13, 2026	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
May 11, 2026	Form 144	Could not read	EDGAR
Apr 7, 2026	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Apr 2, 2026	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Mar 4, 2026	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Feb 24, 2026	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Feb 17, 2026	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Feb 11, 2026	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Feb 5, 2026	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Feb 3, 2026	Form 144	Halozyme Therapeutics HALO	Filing · EDGAR
Dec 11, 2025	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Dec 1, 2025	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Nov 12, 2025	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Oct 3, 2025	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Oct 1, 2025	Form 144	Halozyme Therapeutics HALO	Filing · EDGAR
Sep 4, 2025	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Aug 13, 2025	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Jul 10, 2025	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Jun 24, 2025	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Jun 20, 2025	Form 144	Halozyme Therapeutics HALO	Filing · EDGAR
Feb 24, 2025	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Feb 21, 2025	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Feb 18, 2025	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Feb 14, 2025	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Dec 3, 2024	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Oct 9, 2024	Form 144	Halozyme Therapeutics HALO	Filing · EDGAR
Oct 9, 2024	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Oct 8, 2024	Form 144	Halozyme Therapeutics HALO	Filing · EDGAR
Sep 26, 2024	Form 144	Halozyme Therapeutics HALO	Filing · EDGAR
Sep 26, 2024	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Sep 25, 2024	Form 144	Halozyme Therapeutics HALO	Filing · EDGAR
Sep 24, 2024	Form 144	Halozyme Therapeutics HALO	Filing · EDGAR
Sep 12, 2024	Form 144	Halozyme Therapeutics HALO	Filing · EDGAR
Sep 12, 2024	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Sep 11, 2024	Form 144	Halozyme Therapeutics HALO	Filing · EDGAR
Sep 10, 2024	Form 144	Halozyme Therapeutics HALO	Filing · EDGAR
Aug 15, 2024	Form 144	Halozyme Therapeutics HALO	Filing · EDGAR
Aug 15, 2024	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Aug 14, 2024	Form 144	Halozyme Therapeutics HALO	Filing · EDGAR
Aug 13, 2024	Form 144	Halozyme Therapeutics HALO	Filing · EDGAR
Feb 27, 2024	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Feb 20, 2024	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Feb 16, 2024	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Feb 13, 2024	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Aug 31, 2023	Form 144	Halozyme Therapeutics HALO	Filing · EDGAR
Aug 31, 2023	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Aug 30, 2023	Form 144	Halozyme Therapeutics HALO	Filing · EDGAR
Aug 29, 2023	Form 144	Halozyme Therapeutics HALO	Filing · EDGAR
Aug 17, 2023	Form 144	Halozyme Therapeutics HALO	Filing · EDGAR
Aug 17, 2023	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Aug 16, 2023	Form 144	Halozyme Therapeutics HALO	Filing · EDGAR
Aug 15, 2023	Form 144	Halozyme Therapeutics HALO	Filing · EDGAR
Jul 27, 2023	Form 144	Halozyme Therapeutics HALO	Filing · EDGAR
Jul 27, 2023	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Jul 26, 2023	Form 144	Halozyme Therapeutics HALO	Filing · EDGAR
Jul 25, 2023	Form 144	Halozyme Therapeutics HALO	Filing · EDGAR
Mar 9, 2023	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Mar 1, 2023	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Feb 21, 2023	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Feb 17, 2023	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Feb 14, 2023	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Feb 9, 2023	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Jan 19, 2023	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Dec 15, 2022	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Nov 17, 2022	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Feb 17, 2022	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Feb 14, 2022	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Nov 8, 2021	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Oct 4, 2021	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Sep 7, 2021	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Aug 10, 2021	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Jul 6, 2021	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Jun 7, 2021	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
May 25, 2021	Form 4	Quest Diagnostics	Filing · EDGAR
May 11, 2021	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Apr 5, 2021	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Mar 1, 2021	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Feb 22, 2021	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Feb 17, 2021	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Feb 16, 2021	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Feb 12, 2021	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Feb 1, 2021	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Nov 30, 2020	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Nov 25, 2020	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Aug 14, 2020	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
May 21, 2020	Form 4	Quest Diagnostics	Filing · EDGAR
Feb 24, 2020	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Feb 18, 2020	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Feb 13, 2020	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Feb 12, 2020	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Feb 4, 2020	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Feb 4, 2020	Form 5	Halozyme Therapeutics HALO	Filing · EDGAR
May 16, 2019	Form 4	Quest Diagnostics	Filing · EDGAR
Feb 22, 2019	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Feb 15, 2019	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Feb 14, 2019	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Feb 6, 2019	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Feb 5, 2019	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Oct 3, 2018	Form 4	Quest Diagnostics	Filing · EDGAR
Jul 5, 2018	Form 4	Quest Diagnostics	Filing · EDGAR
Jun 5, 2018	Form 4	Quest Diagnostics	Filing · EDGAR
May 17, 2018	Form 4	Quest Diagnostics	Filing · EDGAR
May 17, 2018	Form 3	Quest Diagnostics	Filing · EDGAR
Feb 23, 2018	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Feb 16, 2018	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Feb 6, 2018	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Feb 5, 2018	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Jan 9, 2018	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Feb 24, 2017	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Feb 7, 2017	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Feb 6, 2017	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Jan 9, 2017	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Sep 2, 2016	Form 4	Relypsa	Filing · EDGAR
Jul 5, 2016	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Jun 23, 2016	Form 4	Relypsa	Filing · EDGAR
Jun 8, 2016	Form 4	Relypsa	Filing · EDGAR
Feb 9, 2016	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Feb 4, 2016	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Jan 7, 2016	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Jan 4, 2016	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Jun 8, 2015	Form 4	Relypsa	Filing · EDGAR
Feb 6, 2015	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Jan 26, 2015	Form 4	Relypsa	Filing · EDGAR
Jan 26, 2015	Form 3	Relypsa	Filing · EDGAR
Jan 6, 2015	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Sep 16, 2014	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Jan 8, 2014	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Jan 8, 2014	Form 3	Halozyme Therapeutics HALO	Filing · EDGAR
Oct 3, 2013	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Sep 5, 2013	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Aug 14, 2013	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
May 15, 2013	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Apr 3, 2013	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Apr 1, 2013	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Feb 6, 2013	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Nov 30, 2012	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Oct 5, 2012	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Sep 6, 2012	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Aug 8, 2012	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Jul 27, 2012	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Apr 3, 2012	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Oct 27, 2011	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Aug 31, 2011	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Aug 31, 2011	Form 3	Onyx Pharmaceuticals	Filing · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 8, 2026, 5:54 AM ET. The filing on SEC.gov is the record.